Proteinase-activated Receptor 2 (PAR2) Decreases Apoptosis in Colonic Epithelial Cells*

Received for publication, September 9, 2014. Published, JBC Papers in Press, October 20, 2014, DOI 10.1074/jbc.M114.610485

Vadim Iablokov, Christina L. Hirota, Michael A. Peplowski, Rithwik Ramachandran, Koichiro Mihara, Morley D. Hollenberg, and Wallace K. MacNaughton

From the Department of Physiology and Pharmacology, the Inflammation Research Network, and the Snyder Institute for Chronic Diseases, University of Calgary, Alberta T2N 4N1, Canada

Background: Inflammatory bowel disease management lacks therapies that heal the epithelial barrier. Results: PAR2 activation increases activities of MEK1/2 and PI3K in intestinal epithelial cells, which blocks apoptosis. Conclusion: Cytokine-induced apoptosis in colonic epithelial cells is inhibited by PAR2 signaling.

The inflammatory bowel diseases (IBD), Crohn disease, and ulcerative colitis are chronic, debilitating conditions of the intestinal tract. IBD prevalence is highest in developed nations, although the incidence of IBD has been steadily increasing in all regions of the world (1). These diseases are difficult to manage medically and, other than colonic resection in the case of ulcerative colitis, there are no cures. A prevailing model for the pathogenesis of IBD implicates the development of an inappropriate immune response to intestinal microbiota that develops in genetically susceptible individuals with a defective epithelial barrier (2). Thus, understanding the pathways that regulate intestinal epithelial function and homeostasis may provide additional targets for therapy.

Epithelial homeostasis is maintained by a finely regulated balance between proliferation and apoptotic cell death. Intestinal epithelial cells arise from a stem cell region at the base of the mucosal crypts and migrate to the mucosal surface where they differentiate and perform functions associated with nutrient digestion, absorption, and host defense before proceeding through a physiological apoptotic program that results in shedding into the lumen (3). However, mucosal tissue from inflamed intestine displays significantly increased apoptosis of intestinal epithelial cells along the entire crypt-to-surface axis (4, 5). The inflammatory cytokine, TNF-α, is thought to be responsible for the increase in epithelial apoptosis observed in IBD. The resultant loss of epithelial homeostasis is associated with increased epithelial permeability to enhance the contact between luminal antigens and intestinal immune cells (6, 7). IFN-γ increases the expression of the TNF receptor and enhances TNF-α-induced apoptosis (8). The ongoing epithelial defect hinders the resolution of intestinal inflammation, which may be mitigated by growth factors that block epithelial apoptosis. For example, epidermal growth factor (EGF) can decrease the severity of dextran sodium sulfate-induced colitis and induce remission in patients with severe ulcerative colitis (9, 10). Mucosal healing...
PAR2 Reduces Colonic Epithelial Apoptosis

has become an important end-point in the clinical management of IBD (11), and the reestablishment of normal intestinal mucosal structure is predictive of long term remission (12). Thus, the identification of new therapies that reestablish epithelial homeostasis to promote mucosal healing may provide new options for IBD patients.

A potential candidate for maintaining intestinal epithelial homeostasis is the G protein-coupled receptor, proteinase-activated receptor 2 (PAR2), which is expressed on intestinal epithelial cells (13, 14). PARs have a unique mechanism of activation, wherein proteolytic cleavage of the extracellular N terminus of the receptor by serine proteinases, which in the case of PAR2 includes trypsin, mast cell tryptase, coagulation factors VIIa/Xa, and kallikrein-related peptidase 14 (15), reveals a new N-terminal amino acid sequence that interacts with the second extracellular loop of the receptor to stimulate G protein- and β-arrestin-dependent signaling (16, 17). Synthetic peptides similar to the revealed “tethered ligand” sequence have been instrumental in identifying the specific functions of PAR2 while controlling for the receptor-independent actions of its activating proteinases. PAR2 activation increases cell proliferation in colonic epithelial cells in an ERK1/2-dependent manner (18). In other cell models, PAR2 activation also stimulates PI3K signaling (19). In this study, we sought to determine whether PAR2 signaling could decrease cytokine-stimulated apoptosis of colonic epithelial cells, based on the contention that even modest changes in the proliferation-apoptosis balance could promote the reestablishment of epithelial homeostasis to drive the resolution of inflammation in IBD. Using the HT-29 colonic epithelial cell line, we show that activation of PAR2 decreases TNF-α- and IFN-γ-induced apoptosis in a MEK1/2- and PI3K-dependent manner. Phosphorylation and activation of the proapoptotic protein, Bcl-2-associated death promoter (BAD), as well as up-regulation of anti-apoptotic myeloid cell leukemia 1 (MCL-1), are not fully responsible for the prosurvival effects of PAR2 activation on intestinal epithelial cells.

EXPERIMENTAL PROCEDURES

Chemicals and Reagents—The PAR2-activating peptides, SLIGRL, SLIGKV, and 2-furoyl-LIGRLO (2f-Li), as well as the inactive reverse peptide, 2-furoyl-OLRGIL-NH₂, were synthesized by Dr. Denis McMaster (Peptide Core Facility, University of Calgary, Calgary, Alberta, Canada). Porcine pancreatic trypsin was purchased from Sigma-Aldrich. Recombinant human interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) were purchased from R&D Systems (Minneapolis, MN). The PI3K inhibitor, LY294002, was purchased from Cayman Chemical (Ann Arbor, MI). The MEK1/2 inhibitors, PD98059 and U0126, were purchased from Promega (Nepean, ON). The p90RSK inhibitor, SL0101, was purchased from Tocris Bioscience (Minneapolis, MN).

Cell Culture—The human colonic adenocarcinoma cell line HT-29 (ATCC, Manassas, VA) was grown in Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 (DMEM/F12, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 100 units/ml penicillin, 100 μg/ml streptomycin, and 5 μg/ml plasmocin (InvivoGen, San Diego, CA). Trypsin was used to detach cells when passing and plating for experiments. Although trypsin does activate PAR2, the receptor has been shown to recycle to the cell surface after 2 h (20). In all of our experiments, cells were used at least 2 days after lifting with trypsin. Cells were serum-starved for 1 h prior to stimulation with PAR2-activating peptides or trypsin. Apoptosis was then induced through the addition of 40 ng/ml IFN-γ for 5 min followed by 10 ng/ml of TNF-α for various time points as described previously (8). Both floating and attached cells were collected for analysis of apoptosis.

Immunoblot—Whole cell lysates were prepared as described previously (21). Whole cell lysates were prepared using a lysis buffer containing 40 mM Tris-HCl, 8 mM EDTA, 1% Triton X-100, and protease inhibitor mixture (Sigma-Aldrich). The phosphatase inhibitors NaF and Na₃VO₄ were added to the lysis buffer when determining levels of phosphorylated proteins. The protein concentrations of whole cell lysates were quantified using the DC Protein Assay Kit by following the manufacturer’s instructions (Bio-Rad). A maximum of 45 μg of protein from each sample was separated by electrophoresis in a Criterion XT Bis-Tris Gel (Bio-Rad), followed by electrical transfer to a nitrocellulose membrane (0.2 μm pore size, Bio-Rad). Membranes were blocked for 1 h at room temperature with either 5% milk or 5% BSA in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBST). Primary antibodies were diluted in 5% milk or 5% BSA TBST and incubated with the membranes overnight at 4 °C, followed by three 5-min washes in TBST and a 1-h incubation at room temperature with 5% milk TBST containing the appropriate secondary antibody conjugated to HRP. Unbound secondary antibody was then removed with three additional 5-min washes in TBST. Immunoblots were developed by enhanced chemiluminescence (ECL, GE Healthcare) using the ChemiDoc gel imaging system (Bio-Rad). Exposure times were varied to eliminate signal saturation. All the membranes were blotted for actin or for total kinases, which were used as loading controls. Background subtraction was applied to all blots using ImageJ (version 1.47v) with the sliding paraboloid algorithm (22). Band intensity was also calculated with ImageJ, which were then normalized by the sum of the replicates as described by Dugasperi et al. (23). Antibodies, sources and catalogue numbers are as follows: cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, catalogue no. 9661), cleaved caspase-9 (Cell Signaling, catalogue no. 9501), cleaved caspase-8 (Cell Signaling, catalogue no. 9496), cleaved poly(ADP-ribose) polymerase (PARP, Cell Signaling, catalogue no. 9542), p44/42 MAPK (Cell Signaling, phospho no. 9106, total no. 9102), Akt (Cell Signaling, phospho no. 9271, total no. 9272), p90RSK (Cell Signaling, phospho no. 9335, total no. 9355), BAD (Cell Signaling, phospho Ser112 no. 9291, phospho Ser136 no. 4366, total no. 9292), actin clone AC-40 (Sigma-Aldrich, no. A4700). Anti-mouse and anti-rabbit IgGs conjugated to HRP (The Jackson Laboratory, Bar Harbor, ME) were used as secondary antibodies.

Flow Cytometry—Floating cells were collected and pooled with attached cells, which were detached using a non-trypsin-containing proprietary solution to prevent activation of PAR2 (HyQtase, Thermo Fisher, Waltham, MA). Harvested cells were washed twice in calcium buffer supplied by the BD
PAR2 Reduces Colonic Epithelial Apoptosis

Pharmigen FITC annexin V apoptosis detection kit (San Diego, CA) to remove any remaining EDTA. Single cell suspensions were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−) were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−) were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−) were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−) were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−) were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−) were stained using the kit in accordance with manufacturer’s instructions. Autofluorescence of cells was examined from the sample expected to have the greatest level of apoptosis. Care was taken to exclude cell debris and doublets. Compensation-adjusted fluorescence from at least 30,000 events was recorded using the Attune flow cytometer (Applied Biosystems). The percentage of early apoptotic cells (annexin V−/PI−)

Transcriptional levels of Caspase9 and PARP were assayed using quantitative PCR. Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and cDNA was generated using the Verso cDNA synthesis kit (Thermo Scientific). Human PAR2 and GAPDH primers were as follows: 5'-AGTGGCACCATCCAAGGAAC-3' (sense) and 5'-UUAGAUAGCCCAAACAGCCTC-3' (antisense) were added to 200 μl of Invitrogen Opti-Mem reduced serum medium (Invitrogen), gently mixed by pipetting, and transferred into a well of a 12-well plate. Ten μl of Lipofectamine RNAiMAX (Invitrogen) was added to each siRNA solution, mixed by gently shaking the plate, and left undisturbed for 15 min at room temperature. One million cells were added to each well in a volume of 800 μl and incubated overnight at 37 °C and 5% CO2. The medium was changed the next day with DMEM/F12 supplemented with 10% FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin.

Quantitative PCR—Total RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. The reverse transcription reaction was performed using 700 ng of total RNA that was reverse-transcribed into cDNA using a random hexamer primer and SuperScript II Reverse Transcriptase (Invitrogen). Quantitative PCR was carried out using Qiagen’s QuantiTect SYBR Green PCR Kit in accordance with the manufacturer’s instructions and performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems, Streetsville, ON). The annealing temperatures for both PAR2 and β-actin primers was 54 °C. Human PAR2 primers were as follows: 5'-AGTGGCACCATCCAAGGAGC-3' (forward) and 5'-TGGAAGGAAGACATGTTGTC-3' (reverse). Human β-actin primers were as follows: 5'-AGAGGGAATCAGTGTG-
TGAC-3’ (forward) and 5’-CAATAGTGAGCTGGC-CGT-3’ (reverse). Relative quantities of mRNA were calculated using the ΔΔC_{T} method using β-actin as the housekeeping gene (24).

**Calcium Signaling**—Functional knockdown of PAR2 by siRNA was verified by monitoring mobilization of intracellular calcium in response to 2f-LI as described previously (17) as an index of cell activation. Cells were detached after siRNA transfection with sterile 0.2 mM EDTA/PBS and incubated with 5 μM of Fluo4-acetoxymethyl ester no-wash (Invitrogen) for 30 min at room temperature in the presence of sulfonpyrazone (0.25 mM). Immediately before the experiment, Fluo4-loaded cells were diluted in calcium buffer (150 mM NaCl, 2 mM KCl, 1.5 mM CaCl_{2}, 20 mM glucose, and 20 mM HEPES in deionized H_{2}O, pH 7.4). Agonist-stimulated calcium mobilization was monitored with the Victor X4 fluorescent plate reader (PerkinElmer). Fluorescence data are expressed as the change in Fluo-4 fluorescence (excitation, 485 nm; emission, 535 nm) between baseline and maximum emission. The continued presence of intracellular Fluo4 in each sample was verified by the addition calcium ionophore, A23187 (Sigma-Aldrich), at the end of the experiment.

**Statistical Analysis**—Comparisons between two groups were made using the Student’s t test. Comparisons between three or more groups were made using a one-way ANOVA, followed by a post hoc Bonferroni’s test for significance. All statistical analyses were made using GraphPad Prism (version 6.0e, GraphPad Software, La Jolla, CA). A p value of < 0.05 was considered significant.

**RESULTS**

**Activation of PAR2 in Colonic Epithelial Cells Decreases IFN-γ and TNF-α-induced Apoptosis**—We chose to use the human colonic epithelial cell line HT-29 because they are

![Graph showing cytokine-induced apoptosis is delayed by PAR2 stimulation.](image)

![Graph showing knockdown of PAR2 sensitizes colonic epithelial cells to cytokine-induced apoptosis.](image)

![Graph showing percentage of cells undergoing apoptosis determined by annexin V and PI staining.](image)
known to express PAR2 and are sensitive to apoptosis stimulated by IFN-γ and TNF-α (8). This cell line resembles differentiated intestinal epithelia, but not crypt stem cells, due to the absence of an important anti-apoptotic protein, BCL-2, which makes them an appropriate model to investigate the cause of increased cell death of differentiated epithelia in IBD (25, 26). Serum-starved HT-29 cells were incubated with 40 ng/ml IFN-γ and 10 ng/ml TNF-α to model an inflammatory environment and investigate the effects of PAR2 activation on epithelial apoptosis. Increased levels of cleaved caspase-8, -9, and -3, and PARP were detected in whole cell lysates after 6 h of incubation (Fig. 1A). Pretreating HT-29 cells with the PAR2 activating peptides 2f-LI or SLIGKV, or with trypsin, significantly decreased cleavage of all caspases studied, as well as PARP (Fig. 1A–E). In experiments using trypsin, the trypsin was removed after 5 min of incubation and replaced with serum-free medium to avoid proteolysis of IFN-γ and TNF-α. A hallmark of apoptosis is the loss of phospholipid symmetry in the plasma mem-
brane resulting in the externalization of phosphatidylserine (PS) from the inner to the outer leaflet (27). The externalization of PS occurs in a caspase-3-dependent manner (28). Thus, PS exposure occurs after caspase-3 and PARP cleavage. An 8-h incubation with IFN-γ and TNF-α was found to maximally increase the percentage of HT-29 cells with externalized PS (data not shown). Preactivation of PAR2 with 2f-LI significantly decreased the percentage of cells displaying this apoptotic marker (Fig. 1, F–G). The observed reduction in apoptosis was dependent on the sequence of 2f-LI because the reverse peptide, 2-furoyl-OL.RGIL, did not alter levels of cytokine-induced cleaved PARP stimulated by IFN-γ and TNF-α (Fig. 1H). Activation of PAR2 prior to the addition of cytokines was not able to decrease levels of cleaved caspases and PARP indefinitely as the inhibitory effect was lost after 8 h (Fig. 2). Thus, activation of PAR2 on colonic epithelial cells with either synthetic activating peptides or trypsin is able to significantly delay the kinetics of proinflammatory cytokine-induced apoptosis.

Knockdown of PAR2 Sensitizes Colonic Epithelial Cells to Cytokine-induced Apoptosis—siRNA was used to decrease PAR2 expression to rule out any nonspecific effects of 2f-LI. PAR2 mRNA was significantly decreased after 24 h with 50 or 100 nM PAR2-specific siRNA compared with cells transfected with a scrambled siRNA (Fig. 3A). Due to the marked differences in the ability of commercially available antibodies to detect PAR2 (29), we recorded intracellular calcium release in response to 2f-LI as a measure of PAR2 function after knockdown. PAR2 siRNA significantly prevented the liberation of intracellular calcium compared with scrambled siRNA when cells were stimulated with 5 and 50 μM of 2f-LI (Fig. 3B). HT-29 cells transfected with siRNA were then incubated with cytokines to stimulate apoptosis, and the externalization of PS was measured by flow cytometry. 2f-LI decreased the proportion of cells with externalized PS in scrambled siRNA-transfected cells, but not in PAR2 siRNA-transfected cells (Fig. 3C). Furthermore, a greater proportion of PAR2 siRNA-transfected cells were observed to have externalized PS in response to cytokines compared with scrambled siRNA-transfected cells. These results indicate that 2f-LI acts specifically through PAR2 to decrease apoptosis. Additionally, these results show that HT-29 cells deficient in PAR2 are more susceptible to cytokine-induced apoptosis and that a baseline level of PAR2 activity may be occurring that prevents greater apoptosis when cells are stimulated with cytokines.

PAR2 Anti-apoptotic Signaling Is Dependent on the Simultaneous Activities of MEK1/2 and PI3K—ERK1/2 and Akt are kinases that have well established roles in promoting cell survival and are activated by MEK1/2 and PI3K, respectively (30, 31). We tested whether PAR2 activates these kinases to block cytokine-induced apoptosis in intestinal epithelial cells. Blocking either the upstream kinase MEK1/2 with U0126 (Fig. 4, A–C) or PI3K with LY294002 (Fig. 4, D–F) did not block the ability of PAR2 to decrease the cleavage of PARP or caspase-3. Blocking either MEK1/2 or PI3K alone did, however, lower the ability of 2f-LI to decrease detected cleaved PARP and cleaved caspase-3, providing evidence that these kinases were important in blocking apoptosis. When these inhibitors were applied concurrently, we observed complete blockage of the ability of PAR2 activation to inhibit caspase-3 and PARP cleavage (Fig. 4, G–I). Additionally, activation of PAR2 decreased PS externalization in the presence of a PI3K inhibitor but not an MEK1/2 inhibitor (Fig. 5). Again, both inhibitors together blocked the PAR2-mediated inhibition of PS externalization. Thus, the concurrent activation of both MEK1/2 and PI3K is required for the anti-apoptotic effect of PAR2 activation.

PAR2 Signaling Increases the Phosphorylation of BAD and Expression of MCL-1 During Cytokine-induced Apoptosis—Increased mitochondrial outer membrane permeability drives the intrinsic apoptotic pathway and is regulated by pro- and anti-apoptotic members of the B-cell lymphoma 2 (BCL-2) protein family (32). The expression of BAX, BAK, BIMEL, BIML, and BCL-XL were not altered by PAR2 activation during cytokine-induced apoptosis, whereas the expression of BCL-2 was not detected in HT-29 whole cell lysates (data not shown) and is in agreement with previous reports (33). Phosphorylation of the sensitizer BH3-only protein BAD and the subsequent release of anti-apoptotic BCL-XL represents a mechanism by which growth factors such as glucagon-like peptide-1 and EGF increase cell survival (34, 35). HT-29 cells were incubated with 2f-LI for up to 3 h to determine whether PAR2 activation resulted in the phosphorylation of BAD. 2f-LI increased the phosphorylation of ERK1/2, the downstream p90 ribosomal S6 kinase (p90RSK) and BAD at the S112 residue after 5 min, which returned to baseline phosphorylation levels after 2 h (Fig. 6A). Phosphorylation of BAD at Ser112 was markedly reduced by inhibition of MEK1/2 or p90RSK using U0126 or SL0101, respectively (Fig. 6B). The kinetics of PAR2-stimulated Akt phosphorylation was similar to ERK1/2 and was accompanied by phosphorylation of BAD at the Ser136 residue (Fig. 6C). The PI3K-selective inhibitor LY294002 blocked the phosphorylation of Akt as well as BAD at Ser136 (Fig. 6D). HT-29 cells
undergoing apoptosis displayed increased BAD phosphorylation at Ser\(^{112}\) and Ser\(^{136}\) when pretreated with 2f-LI compared with cytokines alone at 2 and 4 h but not after 6 h (Fig. 6, F and G). These data show that PAR2 activation results in the phosphorylation of BAD at both the Ser\(^{112}\) and Ser\(^{136}\) positions and that this is driven by the activities of the MEK1/2-ERK1/2-p90RSK and the PI3K-Akt pathways, respectively. Additionally, PAR2 activation in cells undergoing apoptosis displayed increased levels of BAD phosphorylation.

MCL-1 is an anti-apoptotic member of the BCL-2 family under the fine transcriptional control of PI3K and MEK1/2 (36, 37). HT-29 cells were found to express low basal levels of the MCL-1 protein (Fig. 7A). Activation of PAR2 with 2f-LI led to a significant increase in MCL-1 expression after 2 and 4 h (Fig. 7B). Pretreat-
MCL-1 on its own did, however, increase the amount of cleaved PARP detected when cells were pretreated with 2f-LI (Fig. 8, D and E). Concurrent knockdown of BAD and MCL-1 increased the detection of cleaved caspase-3 and cleaved PARP when cells were pretreated with 2f-LI (Fig. 8, G–I). Thus, the absence of both BAD and MCL-1 decreased the ability of PAR2 activation to decrease cleavage of these two apoptotic markers. Neither BAD nor MCL-1 were observed to contribute to decreased PS externalization triggered by PAR2 activation because 2f-LI could decrease detected PS in the absence of one or both of these proteins to levels detected in scrambled siRNA-treated cells (Fig. 9). Absence of BAD in HT-29 cells was observed to increase the effectiveness of 2f-LI in decreasing cytokine-stimulated PS externalization. Taken together, neither BAD nor MCL-1 participate significantly in PAR2-mediated inhibition of cytokine-induced apoptosis in HT-29 colonic epithelial cells.

**DISCUSSION**

Loss of epithelial homeostasis, through apoptosis induced by the cytokines IFN-γ and TNF-α, is a key feature of the pathophysiology that characterizes IBD. Here, we describe a new role for PAR2 in decreasing the kinetics of cytokine-induced apoptosis in colonic epithelial cells. The selective PAR2 agonist, 2f-LI, as well as the prototypical PAR2-activating serine protease, trypsin, were found to slow the cleavage of caspase-9, -8, and -3, and PARP when HT-29 cells were exposed to IFN-γ and TNF-α. PAR2 was found to be directly responsible because its knockdown eliminated the survival response induced by 2f-LI and increased the sensitivity of HT-29 cells to cytokine-stimulated apoptosis. The anti-apoptotic effect of PAR2 activation in HT-29 cells could be blocked when inhibitors of MEK1/2 and PI3K were applied concurrently, thus providing evidence for the requirement of the activity of both kinases downstream of PAR2. We next examined alterations in the BCL-2 protein family, which regulate mitochondrial outer membrane permeability to cytochrome c and activation of caspases. We observed that PAR2 signaling directly regulated the intrinsic apoptotic machinery by stimulating the phosphorylation of BAD and increased MCL-1 expression at time points that preceded changes in caspase cleavage. Through double knockdown studies, however, we found that these BCL-2 family members played only a minimal role in the anti-apoptotic effect of PAR2 activation. A scheme proposing the mechanism whereby PAR2 inhibits cytokine-induced apoptosis is presented in Fig. 10.

Intestinal epithelial cells are uniquely situated to respond to PAR2-activating serine proteases. For example, during inflammation, microvascular leakage allows PAR2-activating coagulation cascade proteases to gain access to the basolateral aspect of the epithelium (38, 39). Indeed, the inhibition of apoptosis by factor VIIa and its co-factor, tissue factor, which can activate PAR2, has been described previously (40, 41). However, while levels of active caspase-3 and DNA fragmentation were all lowered by tissue factor in serum-starved BHK-21 cells expressing factor VIIa (40, 42), these studies did not examine the direct involvement of PAR2 in the anti-apoptotic mechanism, although it is known that BHK-21 cells express PAR2 and the factor VIIa-tissue factor complex activates PAR2 to stimulate intracellular Ca$^{2+}$ release (39, 40). In addition to coagulation

![Graph](https://via.placeholder.com/150)

**FIGURE 7. Activation of PAR2 increases MCL-1 expression.** A, serum-starved HT-29 cells were stimulated with 2f-LI and harvested at the indicated times. MCL-1 protein expression was analyzed by blotting whole cell lysates. Representative blot of n = 3 is shown. B, MCL-1 protein densitometry relative to actin. Statistical analysis was done by one-way ANOVA followed by Bonferroni’s multiple comparisons test (n = 3), *p < 0.05; **p < 0.01 compared with untreated cells. C, serum-starved HT-29 cells were pretreated with 2f-LI for 1 h followed by incubation with IFN-γ and TNF-α for the indicated time. Whole cell lysates were blotted for MCL-1. Representative blot of n = 4 is shown. D, densitometry of MCL-1 protein relative to actin. Statistical analysis was done by unpaired t test (n = 4). *p < 0.05; ***p < 0.001. a.u., arbitrary units.
factors, mast cell-derived tryptase, which can also activate PAR2, has been shown to block Fas-induced apoptosis in rheumatoid synovial fibroblasts, but a role for PAR2 activation was not demonstrated in that study (43). Other proteases, such as the membrane tethered serine protease, matriptase, are expressed by intestinal epithelial cells and regulate barrier function (44), although an anti-apoptotic effect has not been ascribed to them at this point.

We found that colonic epithelial cells became sensitized to apoptosis in the presence of proinflammatory cytokines when PAR2 expression was knocked down with siRNA. These results suggest that HT-29 cells have a basal level of PAR2-mediated signaling activity in the absence of exogenous proteinases or activating peptides. HT-29 cells, along with other colon cancer cells, have been shown to produce active kallikrein-related peptidase 14 and matriptase, which are both capable of activating PAR2 (45–48). Normal human colonic epithelia also expresses trypsinogen IV that, after being cleaved by enteropeptidase to become enzymatically active trypsin, can stimulate PAR2-dependent calcium signaling (49). Apoptosis may be inhibited physiologically through this basal autocrine signaling and is abrogated when PAR2 is absent, leading to greater cell death in the presence of IFN-γ and TNF-α.

It was necessary to block both PI3K and MEK1/2 activities simultaneously in our model to completely reverse the ability of PAR2 activation to reduce levels of cleaved caspase-3, cleaved PARP, and the ratio of cells with externalized phosphatidylserine. This finding indicates that the activity of one pathway could...
compensate for the loss of the other, which may occur at the level of BAD phosphorylation and the subsequent release of BCL-XL. BAD is known to have three serine residues that are phosphorylated, which prevents BAD from dimerizing with BCL-XL and increases its binding to 14-3-3 (50–52). The resulting free BCL-XL inhibits apoptosis by preventing truncation of BID from activating BAX and BAK, which stimulate the release of cytochrome c from the mitochondria (Fig. 10) (53). The phosphorylation of either Ser112 or Ser136 on BAD by MEK1/2- and PI3K-dependent pathways, respectively, are sufficient to stimulate dimerization with 14-3-3 and inhibit apoptosis (54, 55). In our study, PAR2 activation stimulated BAD phosphorylation at both of these residues, which could explain why the inhibition of both PI3K and MEK1/2 was required to reverse the effect of PAR2 activation. Another possible reason for the observed compensatory activities between MEK1/2 and PI3K is that both of these kinases are also involved in regulating MCL-1 expression, a BCL-2 family member with the same anti-apoptotic function as BCL-XL (56, 57). Furthermore, MCL-1 has been reported to be stabilized by ERK1/2-dependent phosphorylation (58).

Knockdown of BAD on its own had no effect on the ability of PAR2 activation to decrease apoptosis as measured by cleaved caspase-3, cleaved PARP, and the ratio of annexin V+/PI−/HT-29 cells. Similarly, we did not see a loss of the PAR2-mediated survival response when MCL-1 expression was decreased. We hypothesized that PAR2 signaling might be acting on both BAD and MCL-1 simultaneously to decrease apoptosis. However, when expression of both proteins was decreased, we observed a minimal effect on the ability of PAR2 activation to inhibit the cleavage of caspase-3 and PARP. Similarly, simultaneous knockdown of BAD and MCL-1 did not prevent PAR2 activation from reducing the degree of apoptosis as measured by PS externalization in cytokine-stimulated cells. Taken together, the data suggest concurrent activation of the MEK1/2 and PI3K pathways but little involvement of the mitochondrion-

Knockdown of BAD and/or MCL-1 does not alter the actions of PAR2 activation on phosphatidylserine externalization. HT-29 cells were transfected with nonspecific siRNA (Scr) or siRNA specific for BAD (100 nm; A–Q), MCL-1 (200 nm; D–F) or both (G–I). The concentration of scrambled siRNA added was equal to the total amount of specific siRNA added. After 48 h, cells were serum-starved and pretreated with 2f-LI for 1 h. Apoptosis was then induced with IFN-α and TNF-α for 6 h followed by determination of annexin V+/PI− cell by flow cytometry. Statistical analysis was done by one-way ANOVA followed by Bonferroni’s multiple comparisons test (n = 4). *, p < 0.05; ***, p < 0.0001.

FIGURE 9. Knockdown of BAD and/or MCL-1 does not alter the actions of PAR2 activation on phosphatidylserine externalization. HT-29 cells were transfected with nonspecific siRNA (Scr) or siRNA specific for BAD (100 nm; A–Q), MCL-1 (200 nm; D–F) or both (G–I). The concentration of scrambled siRNA added was equal to the total amount of specific siRNA added. After 48 h, cells were serum-starved and pretreated with 2f-LI for 1 h. Apoptosis was then induced with IFN-α and TNF-α for 6 h followed by determination of annexin V+/PI− cell by flow cytometry. Statistical analysis was done by one-way ANOVA followed by Bonferroni’s multiple comparisons test (n = 4). *, p < 0.05; ***, p < 0.0001.

FIGURE 10. Activation of PAR2 inhibits cytokine-induced apoptosis. A, the cytokine TNF-α activates the extrinsic apoptotic pathway by binding the TNF receptor (TNFR), which then recruits and stimulates the cleavage of caspase-8. Activated caspase-8 in turn cleaves caspase-3 as well as BID into a truncated form (tBID) to stimulate the intrinsic apoptotic pathway. Truncated BID induces conformational changes in both BAX and BAK, which oligomerize and form channels on the mitochondria’s outer membrane. Cytochrome c, normally found within the mitochondria, passes through these channels into the cytosol where it stimulates the activation of caspase-9. The intrinsic and extrinsic apoptotic pathways intersect by the activation of caspases-3 by cleaved caspase-9. Many proteins vital to the normal functioning of the cell, including PARP, are digested by activated caspase-3 leading to cellular apoptosis. In healthy cells, phosphatidylserine is found on the inner leaflet of the membrane but is externalized during apoptosis in a caspase-3-dependent manner. B, activation of PAR2 stimulates both PI3K and MEK1/2, leading to the phosphorylation of BAD through downstream kinases. Phosphorylated BAD binds 14-3-3 and releases anti-apoptotic BCL-XL into the cytosol. PAR2 also increases the expression of anti-apoptotic MCL-1. Both BCL-XL and MCL-1 inhibit the oligomerization of BAX and BAK stimulated by truncated BID resulting in less mitochondrial permeability. The intrinsic apoptotic pathway is inhibited as a result leading to decreased cleavage and activation of caspase-9 and caspase-3. Cleavage of caspase-8 and PARP is also reduced due to less activated caspase-3 being present. The externalization of PS is also decreased as a result of PAR2 activation and is dependent on the activities of both MEK1/2 and PI3K, but not the presence of MCL-1 and BAD. Thus, we hypothesize that PAR2 activation blocks apoptosis through other mechanisms that are dependent on ERK1/2 and PI3K activity.

Knockdown of BAD and/or MCL-1 does not alter the actions of PAR2 activation on phosphatidylserine externalization. HT-29 cells were transfected with nonspecific siRNA (Scr) or siRNA specific for BAD (100 nm; A–Q), MCL-1 (200 nm; D–F) or both (G–I). The concentration of scrambled siRNA added was equal to the total amount of specific siRNA added. After 48 h, cells were serum-starved and pretreated with 2f-LI for 1 h. Apoptosis was then induced with IFN-α and TNF-α for 6 h followed by determination of annexin V+/PI− cell by flow cytometry. Statistical analysis was done by one-way ANOVA followed by Bonferroni’s multiple comparisons test (n = 4). *, p < 0.05; ***, p < 0.0001.
PAR2 Reduces Colonic Epithelial Apoptosis

associated apoptotic and anti-apoptotic proteins investigated. This was interesting given the role of MAPK and PI3K pathways in regulating proteins such as BAD. For example, PI3K and its downstream messengers have been shown to inhibit the proteolytic activity of caspase-9 as well as preventing BAX translocation to the mitochondria via phosphorylation (59–61). Activation of ERK1/2 also promotes survival by increasing the degradation of proapoptotic BIMEL (62, 63); however, we did not observe any alterations in the expression of BIMEL in our experiments (data not shown). It may be that other proteins known to regulate mitochondrial outer membrane permeability, but not investigated here, may be involved in the anti-apoptotic effect of PAR2 activation. In addition, other targets of MAPK and PI3K activities could play a role, but to elucidate these will require further investigation.

In conclusion, we describe a mechanism by which PAR2 activation can inhibit cytokine-induced apoptosis in colonic epithelial cells. Although the effect was transient, we contend that even a subtle change in the level of apoptosis can have profound effects on reestablishing epithelial homeostasis to drive the resolution of mucosal structure and function in IBD. Activators of PAR2 now comprise a novel group of intestinal growth factors capable of stimulating epithelial survival, in addition to proliferation (18). PAR2 agonists should thus be investigated for their efficacy in ameliorating intestinal diseases such as IBD in which epithelial apoptosis contributes to pathology.

Acknowledgment—We thank Laurie Kennedy from the University of Calgary Flow Cytometry Facility for help with flow cytometry experimental design and data analysis.

REFERENCES

1. Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., and Kaplan, G. G. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54; e42; quiz e30
2. Kaser, A., Zeissig, S., and Blumberg, R. S. (2010) Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573–621
3. Grossmann, J., Walther, K., Artinger, M., Rümmele, P., and Schölmerich, J. (2002) Induction of apoptosis before shedding of human intestinal epithelial cells. Am. J. Gastroenterol. 97, 1421–1428
4. Zeissig, S., Bojarski, C., Buerger, N., Mankertz, J., Zeitz, M., Fromm, M., and Schulzke, J. D. (2004) Downregulation of epithelial apoptosis and barrier repair in active Crohn’s disease by tumour necrosis factor α antibody treatment. Gut 53, 1295–1302
5. Dirisina, R., Katzman, R. B., Goretsky, T., Managlia, E., Mittal, N., Williams, D. B., Qiu, W., Yu, J., Chandel, N. S., Zhang, L., and Barrett, T. A. (2011) p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology 141, 1036–1045
6. Gitter, A. H., Wullstein, F., Fromm, M., and Schulzke, J. D. (2001) Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 121, 1320–1328
7. Kiesslich, R., Duckworth, C. A., Moussata, D., Gloeckner, A., Lim, L. G., Goetz, M., Pritchard, D. M., Galle, P. R., Neurath, M. F., and Watson, A. J. (2012) Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 61, 1146–1153
8. Ossina, N. K., Cannas, A., Powers, V. C., Fitzpatrick, P. A., Knight, J. D., Gilbert, J. R., Shekhtman, E. M., Tomei, L. D., Umansky, S. R., and Kiefer, M. C. (1997) Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem. 272, 16351–16357
9. Procaccino, F., Reinhagen, M., Hoffmann, P., Zeeh, J. M., Lakshmanan, J., McRoberts, J. A., Patel, A., French, S., and Eysselein, V. E. (1994) Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 107, 12–17
10. Sinha, A., Nightingale, J., West, K. P., Berlanga-Acosta, J., and Playford, R. J. (2003) Epidermal growth factor enzymes with oral mesalazine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. 349, 350–357
11. Neurath, M. F., and Travis, S. P. (2012) Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61, 1619–1635
12. Baert, F., Moortgat, L., Van Assche, G., Cae nepeel, P., Vergauwe, P., De Vos, M., Stokkers, P., Hommes, D., Rutgeerts, P., Vermeire, S., D’Haens, G., Belgian Inflammatory Bowel Disease Research Group, and North-Holland Gut Club (2010) Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 138, 463–468; quiz e10–1
13. Kong, W., McConalogue, K., Khi tin, L. M., Hollenberg, M. D., Payan, D. G., Böhm, S. K., and Bunnett, N. W. (1997) Luminal trypsin may regulate enterocytes by proteinase-activated receptor 2. Proc. Natl. Acad. Sci. U.S.A. 94, 8884–8889
14. D’Andrea, M. R., Derian, C. K., Leturcq, D., Baker, S. M., Brunmark, A., Ling, P., Darrow, A. L., Santulli, R. J., Brass, L. F., and Andrade-Gordon, P. (1998) Characterization of proteinase-activated receptor-2 immunoreactivity in normal human tissues. J. Histochem. Cytochem. 46, 157–164
15. Adams, M. N., Ramachandran, R., Yau, M. K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., and Hooper, J. D. (2011) Structure, function and pathophysiology of proteinase activated receptors. Pharmacol. Ther. 130, 248–282
16. DeFea, K. A., Zalesky, J., Thoma, M. S., Déry, O., Mullins, R. D., and Bunnett, N. W. (2000) β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 148, 1267–1281
17. Ramachandran, R., Mihara, K., Mathur, M., Rochdi, M. D., Bouvier, M., Defea, K., and Hollenberg, M. D. (2009) Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol. Pharmacol. 76, 791–801
18. Darmoul, D., Gratio, V., Devaud, H., and Laburthe, M. (2004) Proteinase-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J. Biol. Chem. 279, 20927–20934
19. Wang, P., Kumar, P., Wang, C., and Defea, K. A. (2007) Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110α and β by proteinase-activated receptor 2 and β-arrestins. Biochem. J. 408, 221–230
20. Déry, O., Thoma, M. S., Wong, H., Grady, E. F., and Bunnett, N. W. (1999) Trafficking of proteinase-activated receptor-2 and β-arrestin-1 tagged with green fluorescent protein. β-Arrestin-dependent endocytosis of a proteinase receptor. J. Biol. Chem. 274, 18524–18535
21. Hirota, C. L., Moreau, F., Iablokov, V., Dicay, M., Renaux, B., Hollenberg, M. D., and MacNaughton, W. K. (2012) Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G111–G119
22. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to Image: 25 years of image analysis. Nat. Methods 9, 671–675
23. Degasperi, A., Birtwistle, M. R., Volinsky, N., and Rauch, J. (2014) Evaluating strategies to normalise biological replicates of Western blot data. PLoS One 10.1371/journal.pone.0087293
24. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108
25. Hockenberg, D. M., Zutter, M., Hickey, W., Nahm, M., and Korsmeyer, S. J. (1991) BCL2 protein is topographically restricted in tissues characterised by apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 88, 6961–6965
26. Iwamoto, M., Koji, T., Makiyama, K., Kobayashi, N., and Nakane, P. K. (1996) Apoptosis of crypt epithelial cells in ulcerative colitis. J. Pathol. 180, 152–159
27. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., and...
